The trajectory of Sildenafil presents a challenging picture for shareholders. While the initial introduction generated significant profits, the end of its intellectual property protection opened the floodgates to generic alternatives, dramatically reducing sales. This poses a particular challenge for drug manufacturers relying on related blockbuste

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in revenue , its patent expiration created a deluge of lower-priced alternatives , significantly eroding its position . While specific firms may attempt to capitalize on similar conditions , the